Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | F7 | P08709 | 3/20 | 0.47 |
| ▸ | F3 | P13726 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700806 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL3705382 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL3705379 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL289575 | 0.90 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL289576 | 0.90 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL2784802 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL2784807 | 0.89 | ALDH1A1 (0.53) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL2784608 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL2784610 | 0.87 | ALDH1A1 (0.55) | ALDH1A1MAPTCYP19A1PPARGOXER1 | |
| SCHEMBL18944613 | 0.85 | ALDH1A1 (0.54) | ALDH1A1MAPTCYP19A1PPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-08-07 | — | — | US | disclosed |
| US-8735436-B2 | Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas | PRONOVA BIOPHARMA NORGE AS (NO) | 2014-05-27 | — | — | US | disclosed |
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | PRONOVA BIOPHARMA NORGE AS (NO) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122940-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 695/4885MAPT 4175/4885CYP19A1 1476/4885 |
| US-20140221439-A1 | POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF DISEASES RELATED TO CARDIOVASCULAR, METABOLIC AND INFLAMMATORY DISEASE AREAS | FFAR2, FFAR3, FFAR1 | ALDH1A1 663/4885MAPT 4130/4885CYP19A1 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.